Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROXI-PALISADE: REGN7508 and REGN9933 in Peripheral Artery Disease
NCT07318610Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- Aug 2029
- Countries
- 2
01
Overview
A Phase 3 trial of cenvacibart, amrecibart in peripheral artery disease (PAD), sponsored by Regeneron Pharmaceuticals. Started Jul 2026; status: recruiting.
02
Drugs
cenvacibartamrecibart
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT07318610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07318610.